GO
Loading...

Actavis Inc

More

  • Last year Hertz adopted a so-called poison pill to prevent any one shareholder from gaining control of the company as activist investors began circling.

  • Icahn reveals stake in Hertz, plans to push management Wednesday, 20 Aug 2014 | 5:04 PM ET

    BOSTON, Aug 20- Billionaire investor Carl Icahn said on Wednesday that he owns an 8.5 percent stake in Hertz Global Holdings Inc and plans to pressure the rental car company's management over accounting issues and operational failures.

  • US STOCKS-Wall Street rises, biotech shares lead rally Wednesday, 13 Aug 2014 | 2:56 PM ET

    NEW YORK, Aug 13- U.S. stocks rose on Wednesday, with the Dow returning to positive territory for the year as the market shrugged off weak earnings reports and a slump in retail shares. Biotech shares surged, with the Nasdaq biotech index climbing 2.1 percent on the back of stocks including InterMune Inc and Jazz Pharmaceuticals PLC.

  • Aug 5- Generic drug maker Actavis Plc's full-year profit forecast missed analysts' estimates, sending its shares down about 3 percent in premarket trading. Actavis said it expects profit of $13.02- $13.32 per share for the year ending x, below Wall Street estimates of $13.73 per share. Excluding items, Actavis earned $3.42 per share in the second quarter.

  • Drugmaker Actavis posts 34 pct rise in revenue Tuesday, 5 Aug 2014 | 7:36 AM ET

    Aug 5- Generic drug maker Actavis Plc's quarterly revenue rose 34 percent due to strong growth in its North America business. The company had a net profit of $48.7 million, or 28 cents per share, attributable to shareholders for the second quarter ended June 30. Excluding items, Actavis earned $3.42 per share in the second quarter.

  • Cramer: Get this company on your radar, now! Monday, 4 Aug 2014 | 6:33 PM ET

    Ahead of earnings, Jim Cramer thinks you should know about this stock and the potential it presents.

  • NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

  • Cooperman: Buy these stocks now Wednesday, 16 Jul 2014 | 12:22 PM ET
    Omega Advisors CEO Leon G. Cooperman speaks at the CNBC Institutional Investor Delivering Alpha Conference in New York.

    Billionaire investor Leon Cooperman gave 12 stock recommendations at the Delivering Alpha conference Wednesday.

  • Hedge fund manager Cooperman says market gains will slow Wednesday, 16 Jul 2014 | 12:19 PM ET

    NEW YORK, July 16- Hedge fund manager Leon Cooperman, who has forecast that the Standard& Poor's 500 stock index will hit 2000 this year, cautioned on Wednesday that gains will be slower as the market is more fairly valued now.

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • Mylan nears major deal for Abbott drugs: Sources Friday, 11 Jul 2014 | 6:42 PM ET

    U.S. generic drugmaker Mylan is said to be in advanced talks to buy a multibillion-dollar portfolio of established products from Abbott Laboratories.

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.

  • Medical technology group Medtronic Inc said last month that it plans to buy Covidien Plc, a rival based in low-tax Ireland. The research service said other inversions have been done in the past decade by Mallinckrodt Pharmaceuticals, Perrigo Co Plc, Actavis Plc and other companies, many of them rebasing for tax purposes to Ireland.

  • Early movers: NFLX, WYNN, APP & more Tuesday, 1 Jul 2014 | 7:56 AM ET

    Some of the names on the move ahead of the open.

  • WASHINGTON, June 30- Generic drugmaker Actavis Plc has won U.S. approval to buy specialty pharmaceuticals company Forest Laboratories on condition it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.

  • Why rivals are jealous of Pfizer's AstraZeneca deal Thursday, 1 May 2014 | 7:15 AM ET
    U.S. drugmaker Pfizer proposed buying AstraZeneca for about 58.8 billion pounds ($98.7 billion) in what would rank as the industry's biggest-ever takeover, surpassing Pfizer's $64 billion purchase of Wyeth in 2009.

    As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.

  • Focus is on Fed, but this may move markets instead Wednesday, 30 Apr 2014 | 9:30 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Wall Street has its eye on the Federal Reserve's meeting, but a slew of data is likely to have more influence on stocks Wednesday.

  • Early movers: CMCSA, PFE, AZN, GE & more Monday, 28 Apr 2014 | 8:02 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Cramer’s game plan: Stock strategies amid earnings Friday, 25 Apr 2014 | 6:07 PM ET

    With the market in the thick of earnings, next week promises to be an eventful five days for investors. Are you ready? Cramer sure is.

  • Pfizer-AstraZeneca deal? Not as crazy as it sounds Monday, 21 Apr 2014 | 6:24 PM ET
    Cholesterol drugs, Crestor, left, manufactured by AstraZeneca Plc, and Lipitor, manufactured by Pfizer Inc.

    There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.